Online inquiry

IVTScrip™ mRNA-Anti-GPI-APs, PRX-302(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ13561MR)

This product GTTS-WQ13561MR is a type of mRNA modified with 5-Methoxy-UTP, which ecodes the monoclonal antibody that targets GPI-APs gene. The antibody can be applied in Benign prostatic hyperplasia research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Aeromonas hydrophila
RefSeq NM_000615.7; NM_001144822.2; NM_000591.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4684; 965; 929
UniProt ID P13591; P19256; P08571
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-GPI-APs, PRX-302(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ13561MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11612MR IVTScrip™ mRNA-Anti-CD3E&IL3RA, MGD-006(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA MGD-006
GTTS-WQ4479MR IVTScrip™ mRNA-Anti-CD28, BMS-931699(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BMS-931699
GTTS-WQ5601MR IVTScrip™ mRNA-Anti-IL13, CDP7766(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CDP7766
GTTS-WQ14554MR IVTScrip™ mRNA-Anti-IL13&IL4, SAR156597(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA SAR156597
GTTS-WQ8537MR IVTScrip™ mRNA-Anti-CD4, Hu5A8(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA Hu5A8
GTTS-WQ3648MR IVTScrip™ mRNA-Anti-FGFR2, BAY 1187982(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA BAY 1187982
GTTS-WQ3436MR IVTScrip™ mRNA-Anti-HGF, AV-299(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA AV-299
GTTS-WQ9186MR IVTScrip™ mRNA-Anti-FOLR1, IMGN853(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA IMGN853
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW